Novartis’ Cosentyx (secukinumab) failed to show significant superiority over AbbVie’s Humira (adalimumab) in a head-to-head trial in psoriatic arthritis (PsA). Although Cosentyx showed numerically ...

Novartis has launched two trials pitting its new Cosentyx product against AbbVie’s Humira and one of its biosimilars in a bid to capture market share from the world’s biggest-selling drug. The two ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

AbbVie's blockbuster Humira still holds the crown for being the world’s best selling drug. Novartis has announced that despite “encouraging” results, its psoriatic arthritis drug Cosentyx (secukinumab ...

Basel, January 9, 2018 - Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx ® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondylitis ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections to treat several inflammatory conditions. Adults and certain children can receive this medication to treat ...

Eli Lilly’s Taltz and Novartis’ Cosentyx have been battling it out lately in the next-gen psoriatic arthritis field. But Lilly’s drug has a big win under its belt that Novartis can’t tout. Friday, the ...

The FDA has approved Novartis AG’s (NYSE: NVS) Cosentyx (secukinumab) to treat moderate to severe plaque psoriasis in pediatric patients six years and older and are candidates for systemic therapy or ...

Novartis has unveiled trial results which it says show that Cosentyx is the first and only IL-17A inhibitor to potentially modify the course of psoriasis. Novartis has unveiled trial results which it ...

The 2025 European Academy of Dermatology and Venereology (2025 EADV), the largest dermatology conference in Europe, opened on the 17th (local time) in Paris, France. Running through the 20th, EADV ...